drugset
drugset / Trial / NCT00643643

Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

NCT00643643 ↗

Phase 2 Completed 41 enrolled ViiV Healthcare Pfizer · collab
RandomizedSingle-groupDouble-blindTreatment

Summary

To investigate the relationship between the pharmacokinetics and pharmacodynamics of UK-427,857 and its antiviral effects in patients with human immunodeficiency virus (HIV).

Timeline

Start
2002-10
Primary completion
2003-06
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified 25 mg Oral
Subject Maraviroc Other / unclassified 50 mg Oral
Subject Maraviroc Other / unclassified 100 mg Oral
Subject Maraviroc Other / unclassified 300 mg Oral

Indications

HIV infectious disease